Literature DB >> 16862660

Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab.

Teresa Ruiz-Jimeno, Alejandra Carvajal, Cristina Mata, Elena Aurrecoechea.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16862660

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  10 in total

1.  Neurological complications of biologic therapy in psoriasis: a review.

Authors:  Mark Bechtel; Catherine Sanders; Ann Bechtel
Journal:  J Clin Aesthet Dermatol       Date:  2009-11

2.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 3.  Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors:  Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

4.  Central nervous system demyelination associated with etanercept in a 51 years old woman.

Authors:  Wanis H Ibrahim; Mohammed Hammoudah; Naveed Akhtar; Hassan Al-Hail; Dirk Deleu
Journal:  Libyan J Med       Date:  2007-06-01       Impact factor: 1.657

5.  Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature.

Authors:  Rana Alnasser Alsukhni; Ziena Jriekh; Yasmin Aboras
Journal:  Case Rep Med       Date:  2016-10-20

Review 6.  CNS Demyelination with TNF-α Blockers.

Authors:  Elissavet Kemanetzoglou; Elisabeth Andreadou
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

7.  PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

Authors:  Sinah Engel; Felix Luessi; Aneka Mueller; Rudolf E Schopf; Frauke Zipp; Stefan Bittner
Journal:  Ther Adv Neurol Disord       Date:  2020-01-02       Impact factor: 6.570

8.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16

9.  Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.

Authors:  Evripidis Kaltsonoudis; Anastasia K Zikou; Paraskevi V Voulgari; Spyridon Konitsiotis; Maria I Argyropoulou; Alexandros A Drosos
Journal:  Arthritis Res Ther       Date:  2014-06-17       Impact factor: 5.156

10.  Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists.

Authors:  Claudia Bruè; Cesare Mariotti; Ilaria Rossiello; Andrea Saitta; Alfonso Giovannini
Journal:  Case Rep Ophthalmol       Date:  2016-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.